YB
BannerBanner

British attitude to gyno

Author
ookaak
Universe Member
  • Total Posts : 398
  • Reward points: 9424
  • Joined: 2006/01/16 22:38:13
  • Status: offline
2006/07/19 18:55:33 (permalink)
0

British attitude to gyno

i've noticed on the forums that there seem to be more british people getting gyno than the americans. Is this because they usually run an AI and anti-E throughout their course or is it because they use different meds. it seems to me that the genral idea in britton is to run nolva if you need it where the yanks run it if they need it or not.

Any ideas?
#1

10 Replies Related Threads

    POWERHOUSE585
    Pro-Member
    • Total Posts : 6784
    • Reward points: 4431
    • Joined: 2003/06/11 18:19:09
    • Location: uk
    • Status: offline
    RE: British attitude to gyno 2006/07/19 19:02:28 (permalink)
    0
    i see where your coming from
    and its true
    my take is why take somthing that isnt needed and im sure many guy take it and its nt needed
    #2
    ookaak
    Universe Member
    • Total Posts : 398
    • Reward points: 9424
    • Joined: 2006/01/16 22:38:13
    • Status: offline
    RE: British attitude to gyno 2006/07/19 19:10:15 (permalink)
    0
    But is prevention not better than cure? why start manageing a problem that your going to have to put up with for the rest of your life when you could prevent it in the first place.i see your point that there is no point in taking something if you don't need it but with gyno you don't know you need nolva until you have it. i'm only saying cuz i've noticed alot of gyno questions lately especially from people using for the first time.
    #3
    PartyBoy
    Moderator
    • Total Posts : 28685
    • Reward points: 13568
    • Joined: 2003/01/14 15:49:53
    • Location: The Lakes, UK
    • Status: offline
    RE: British attitude to gyno 2006/07/19 19:28:34 (permalink)
    0
    Gyno doesn't suddenly appear. There are warning signs that alert you to take action.

    Nolva is not something you would want to take without reason.

    #4
    mrplow
    Pro-Member
    • Total Posts : 1119
    • Reward points: 4785
    • Joined: 2005/03/13 11:02:28
    • Location: the corner buying dope for me nan.
    • Status: offline
    RE: British attitude to gyno 2006/07/19 20:14:01 (permalink)
    0

    ORIGINAL: PartyBoy

    Gyno doesn't suddenly appear. There are warning signs that alert you to take action.

    Nolva is not something you would want to take without reason.


    why say that mate,is it nasty stuff then.cheers.
    #5
    POWERHOUSE585
    Pro-Member
    • Total Posts : 6784
    • Reward points: 4431
    • Joined: 2003/06/11 18:19:09
    • Location: uk
    • Status: offline
    RE: British attitude to gyno 2006/07/19 20:29:30 (permalink)
    0
    nolvadex is liver toxic to an extent
    anything that raises liver values will have an effect on many things
    #6
    mrplow
    Pro-Member
    • Total Posts : 1119
    • Reward points: 4785
    • Joined: 2005/03/13 11:02:28
    • Location: the corner buying dope for me nan.
    • Status: offline
    RE: British attitude to gyno 2006/07/19 20:58:24 (permalink)
    0
    cheers mate
    #7
    PartyBoy
    Moderator
    • Total Posts : 28685
    • Reward points: 13568
    • Joined: 2003/01/14 15:49:53
    • Location: The Lakes, UK
    • Status: offline
    RE: British attitude to gyno 2006/07/19 21:38:03 (permalink)
    0
    Skin rashes(including isolated reports of erythema multiforme, Stevens- Johnson syndrome and bullous pemphigoid) and rare hypersensitivity reactions, including angioedema, have been reported.

    A small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.

    Falls in platelet count, usually to 80,000-90,000 per cu mm but occasionally lower, have been reported in patients receiving tamoxifen for breast carcinoma.

    A number of cases of visual disturbance including reports ofcorneal changesand retinopathyand an increased incidence of cataracts, have been described in patients receiving tamoxifen therapy.

    Uterine fibroids, endometriosis and otherendometrial changes includinghyperplasia and polyps have been reported.

    Cystic ovarian swellings have occasionally been observed in pre-menopausal women receiving tamoxifen.

    Leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. Neutropenia has been reported on rare occasions; this can sometimes be severe.

    Cases of deep vein thrombosis and pulmonary embolism have been reported during tamoxifen therapy (see sections 4.3, 4.4 and 4.5). When tamoxifen is used in combination with cytotoxic agents, there is an increased risk of thrombo-embolic events.

    Very rarely, cases of interstitial pneumonitis have been reported.

    Tamoxifen has been associated with changes in liver enzyme levels and rarely with more severe liver abnormalities including fatty liver, cholestasis and hepatitis.

    Rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen.

    An increased incidence of endometrial cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with tamoxifen treatment.


    A known carcinogen

    http://cdfc.rug.ac.be/HealthRisk/cytostatics/specific_classification/IARC.htm

    Fortunately for men the known cancer that tamoxifen causes in humans is Endometrial cancer (Uterus). However in animal studies it has been shown to cause Hepatocellular cancer (Liver).




    : Expert Opin Drug Saf. 2002 Sep;1(3):253-67.


    Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.

    Brown K.

    Cancer Biomarkers and Prevention Group, The Biocentre, University of Leicester, University Road, Leicester, LE1 7RH, UK. kb20@le.ac.uk

    The anti-oestrogen tamoxifen, which is widely used as adjuvant therapy for breast cancer, is undergoing evaluation as a chemopreventive agent in women at increased risk of developing this disease. Recent results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 prevention trial show a 49% reduction in breast cancer incidence in healthy, high-risk women. However, tamoxifen treatment has the serious side effect of increasing the incidence of endometrial cancer in women and long-term administration of tamoxifen causes hepatic tumours in rats. These liver tumours are induced via a genotoxic mechanism, but the mechanisms responsible for endometrial cancer in women are not yet known and are a focus of much debate. This review describes the findings from the chemoprevention trials and problems associated with the use of tamoxifen in this setting. The mechanism of carcinogenesis in rat liver is explained in detail and compared to the situation in humans, with a view to assessing the risks associated with tamoxifen therapy and predicting whether other anti-oestrogens might be safer alternatives.


    #8
    Mr.Twitch
    Olympian Member
    • Total Posts : 797
    • Reward points: 1604
    • Joined: 2006/06/07 03:16:36
    • Status: offline
    RE: British attitude to gyno 2006/07/19 21:42:03 (permalink)
    0
    good observation ookaak..
    i choose to run nolvadex and ldex during my cycles
    #9
    twistywizard
    Senior Member
    • Total Posts : 144
    • Reward points: 4553
    • Joined: 2005/10/10 23:59:36
    • Status: offline
    RE: British attitude to gyno 2006/07/19 23:49:15 (permalink)
    0
    How do women get away with running it for so long?

    Some are on it for months or a year or so?

    Or is it a case of pot luck!
    #10
    PartyBoy
    Moderator
    • Total Posts : 28685
    • Reward points: 13568
    • Joined: 2003/01/14 15:49:53
    • Location: The Lakes, UK
    • Status: offline
    RE: British attitude to gyno 2006/07/20 09:32:17 (permalink)
    0
    It is used as part of cancer treatment so the benefits of using far outweigh the potential side effects.

    #11
    Jump to:
    ©2018 All content is copyright of MuscleTalk.co.uk and its use elsewhere is prohibited.
    (posting guidelines | privacy | advertise | earnings disclaimer | contact us | supported by)
    © 2018 APG vNext Commercial Version 5.5